According to Prothena's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.9348. At the end of 2023 the company had a P/S ratio of 21.3.
Year | P/S ratio | Change |
---|---|---|
2023 | 21.3 | -63.01% |
2022 | 57.7 | 402.84% |
2021 | 11.5 | -97.96% |
2020 | 562 | -27.56% |
2019 | 776 | 80.47% |
2018 | 430 | 720.86% |
2017 | 52.4 | -96.74% |
2016 | > 1000 | 19.52% |
2015 | > 1000 | 11933.6% |
2014 | 11.2 | -98.7% |
2013 | 857 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Amarin Corporation
AMRN | 1.18 | -90.89% | ๐ฎ๐ช Ireland |
Alnylam Pharmaceuticals
ALNY | 9.56 | -26.11% | ๐บ๐ธ USA |
Alkermes ALKS | 2.47 | -80.92% | ๐ฎ๐ช Ireland |